Werewolf Therapeutics, Inc.
NASDAQ:HOWL
1.44 (USD) • At close January 8, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 1.143 | 0.742 | 1.501 | 5.897 | 8.081 | 4.464 | 7.283 | 4.97 | 4.148 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0.454 | 0.464 | 0.46 | 0.445 | 0.773 | 0.761 | 0.558 | 0.708 | 13.887 | 0.481 | 0.059 | 0.239 | 0.232 | 0.205 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0.689 | 0.278 | 1.041 | 5.452 | 7.308 | 3.703 | 6.725 | 4.262 | -9.739 | -0.481 | -0.059 | -0.239 | -0.232 | -0.205 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0.603 | 0.375 | 0.694 | 0.925 | 0.904 | 0.83 | 0.923 | 0.858 | -2.348 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 12.528 | 15.271 | 12.908 | 9.649 | 10.838 | 9.583 | 11.706 | 15.859 | 13.07 | 13.887 | 10.945 | 13.4 | 9.787 | 7.265 | 4.817 | 5.286 | 4.812 | 3.78 | 2.763 |
| General & Administrative Expenses
| 4.596 | 4.832 | 4.996 | 4.814 | 4.31 | 4.565 | 4.981 | 4.603 | 4.439 | 5.233 | 4.421 | 4.484 | 4.008 | 3.691 | 2.635 | 2.106 | 1.241 | 1.285 | 1.131 |
| Selling & Marketing Expenses
| 0 | -0.454 | -0.464 | -0.46 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 4.596 | 4.378 | 4.532 | 4.354 | 4.31 | 4.565 | 4.981 | 4.603 | 4.439 | 5.233 | 4.421 | 4.484 | 4.008 | 3.691 | 2.635 | 2.106 | 1.241 | 1.285 | 1.131 |
| Other Expenses
| 0 | 1.613 | -0.001 | -0.006 | 0.966 | -0.025 | 0.241 | 1.249 | 0.003 | 0.281 | 0 | 0.015 | 0 | -0.016 | -0.016 | -0.038 | 0 | 7.298 | 0 |
| Operating Expenses
| 17.124 | 19.649 | 17.44 | 14.003 | 15.148 | 14.148 | 16.687 | 20.462 | 17.509 | 19.12 | 15.366 | 17.884 | 13.795 | 10.956 | 7.452 | 7.392 | 6.053 | 5.065 | 3.894 |
| Operating Income
| -17.124 | -18.96 | -17.162 | -12.962 | -9.251 | -6.067 | -12.223 | -13.179 | -12.539 | -14.972 | -15.366 | -17.884 | -13.795 | -10.956 | -7.452 | -7.392 | -6.053 | -5.065 | -3.894 |
| Operating Income Ratio
| 0 | -16.588 | -23.129 | -8.636 | -1.569 | -0.751 | -2.738 | -1.81 | -2.523 | -3.609 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.451 | 1.711 | 0.969 | 0.959 | 0.966 | 0.969 | 0.241 | 1.249 | 0.596 | 0.378 | 0.023 | 0.015 | 0.037 | 0.035 | 0.017 | -0.01 | -0.015 | 7.322 | 0.067 |
| Income Before Tax
| -16.673 | -17.249 | -16.193 | -12.003 | -8.285 | -5.098 | -11.982 | -11.93 | -11.943 | -14.594 | -15.343 | -17.869 | -13.758 | -10.921 | -7.435 | -7.402 | -6.068 | 2.257 | -3.827 |
| Income Before Tax Ratio
| 0 | -15.091 | -21.823 | -7.997 | -1.405 | -0.631 | -2.684 | -1.638 | -2.403 | -3.518 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | -0 | 2.105 | -0.445 | -0.994 | -0.666 | -1.249 | -0.596 | -0.378 | -0.023 | -0.048 | -0.172 | -0.051 | -0.033 | -0.028 | 0 | -0.024 | 0 |
| Net Income
| -16.673 | -17.249 | -16.193 | -12.003 | -8.285 | -5.098 | -11.316 | -10.681 | -11.347 | -14.216 | -15.32 | -17.869 | -13.758 | -10.921 | -7.435 | -7.402 | -6.068 | 2.257 | -3.827 |
| Net Income Ratio
| 0 | -15.091 | -21.823 | -7.997 | -1.405 | -0.631 | -2.535 | -1.467 | -2.283 | -3.427 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.38 | -0.4 | -0.39 | -0.33 | -0.23 | -0.14 | -0.33 | -0.35 | -0.38 | -0.52 | -0.56 | -0.66 | -0.51 | -0.62 | -0.28 | -0.83 | -0.68 | 0.25 | -0.43 |
| EPS Diluted
| -0.38 | -0.4 | -0.39 | -0.33 | -0.23 | -0.14 | -0.33 | -0.35 | -0.38 | -0.52 | -0.56 | -0.66 | -0.51 | -0.62 | -0.28 | -0.83 | -0.68 | 0.25 | -0.43 |
| EBITDA
| -16.67 | -15.653 | -14.726 | -10.304 | -8.806 | -4.325 | -11.221 | -12.762 | -12.135 | -14.787 | -15.268 | -17.81 | -13.728 | -10.894 | -7.413 | -7.348 | -6.012 | -5.023 | -3.871 |
| EBITDA Ratio
| 0 | -16.191 | -22.504 | -8.329 | -1.569 | -0.697 | -2.738 | -1.81 | -2.442 | -3.565 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |